Ahmad Sayeed, Zahiruddin Sultan, Parveen Bushra, Basist Parakh, Parveen Abida, Parveen Rabea, Ahmad Minhaj
Bioactive Natural Product Laboratory, Department of Pharmacognosy and Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard (Deemed University), New Delhi, India.
Centre for Translational and Clinical Research, Jamia Hamdard (Deemed University), New Delhi, India.
Front Pharmacol. 2021 Mar 2;11:578970. doi: 10.3389/fphar.2020.578970. eCollection 2020.
The cases of COVID-19 are still increasing day-by-day worldwide, even after a year of its first occurrence in Wuhan city of China. The spreading of SARS-CoV-2 infection is very fast and different from other SARS-CoV infections possibly due to structural differences in S proteins. The patients with severe diseases may die due to acute respiratory distress syndrome (ARDS) caused by systemic inflammatory reactions due to the excessive release of pro-inflammatory cytokines and chemokines by the immune effector cells. In India too, it is spreading very rapidly, although the case fatality rate is below 1.50% (https://www.statista.com), which is markedly less than in other countries, despite the dense population and minimal health infrastructure in rural areas. This may be due to the routine use of many immunomodulator medicinal plants and traditional AYUSH formulations by the Indian people. This communication reviews the AYUSH recommended formulations and their ingredients, routinely used medicinal plants and formulations by Indian population as well as other promising Indian medicinal plants, which can be tested against COVID-19. Special emphasis is placed on Indian medicinal plants reported for antiviral, immunomodulatory and anti-allergic/anti-inflammatory activities and they are categorized for prioritization in research on the basis of earlier reports. The traditional AYUSH medicines currently under clinical trials against COVID-19 are also discussed as well as furtherance of pre-clinical and clinical testing of the potential traditional medicines against COVID-19 and SARS-CoV-2. The results of the clinical studies on AYUSH drugs will guide the policymakers from the AYUSH systems of medicines to maneuver their policies for public health, provide information to the global scientific community and could form a platform for collaborative studies at national and global levels. It is thereby suggested that promising AYUSH formulations and Indian medicinal plants must be investigated on a priority basis to solve the current crisis.
即使在中国武汉市首次出现新冠病毒一年之后,全球范围内的新冠肺炎病例仍在逐日增加。严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的传播非常迅速,可能由于S蛋白的结构差异,它与其他SARS-CoV感染有所不同。重症患者可能因免疫效应细胞过度释放促炎细胞因子和趋化因子导致全身炎症反应,进而引发急性呼吸窘迫综合征(ARDS)而死亡。在印度,尽管农村地区人口密集且卫生基础设施薄弱,但新冠病毒的传播速度也非常快,不过病死率低于1.50%(https://www.statista.com),明显低于其他国家。这可能是由于印度民众经常使用多种免疫调节药用植物和传统阿育吠陀配方。本文综述了阿育吠陀推荐的配方及其成分、印度民众经常使用的药用植物和配方,以及其他有前景的可针对新冠肺炎进行测试的印度药用植物。特别强调了报道具有抗病毒、免疫调节和抗过敏/抗炎活性的印度药用植物,并根据早期报告对它们进行分类,以便在研究中确定优先次序。还讨论了目前正在针对新冠肺炎进行临床试验的传统阿育吠陀药物,以及对潜在传统药物针对新冠肺炎和SARS-CoV-2进行临床前和临床试验的推进情况。阿育吠陀药物的临床研究结果将指导阿育吠陀医学体系的政策制定者调整其公共卫生政策,为全球科学界提供信息,并可为国家和全球层面的合作研究搭建平台。因此,建议优先研究有前景的阿育吠陀配方和印度药用植物,以解决当前的危机。